Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Summary

To evaluate the feasibility, effectiveness and safety of chidamide combined with venetoclax and azacitidine in the treatment of newly diagnosed acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy.

Eligibility

Inclusion Criteria:

* （1）Age ≥18 years old, no gender limit ;
* （2）be diagnosed with AML (non-M3) according to WHO 2016 standards;
* （3）No previous treatment;
* （4）Ineligible for intensive chemotherapy based on the following definitions: ≥75 years of age or 18 to 74 years of age with at least one of the following comorbidities: Eastern Cooperative Oncology Group (ECOG) performance status of 2 or 3 A history of cardiac disease such as congestive heart failure Treatment is required, or ejection fraction ≤ 50%, or chronic stable angina, diffusing capacity of lung for carbon monoxide (DLCO) ≤ 65%, or forced expiratory volume in first second (FEV1) ≤ 65%, creatinine clearance ≥ 30 mL/min to \< 45 mL/min, moderate hepatic impairment, total bilirubin \> 1.5 to ≤ 3.0 × ULN, other comorbidities that are not suitable for intensive chemotherapy in the physician's judgment.
* （5）Subjects must have an ECOG performance status score of: 0 to 2 for subjects aged ≥ 75 years or 0 to 3 for subjects aged ≥ 18 to 74 years.
* （6）Other comorbidities that are not suitable for intensive chemotherapy in the doctor's judgment;
* （7）Expected survival time ≥3 months;
* （8）Have the ability to understand and be willing to sign the informed consent form for this study.

Exclusion Criteria:

* (1) Combined with other malignant tumors
* (2) Have ever received treatment with chidamide and / or venetoclax or azacitidine;
* (3) The risk is assessed as low risk according to the NCCN 2022 guidelines \[t(8;21)(q22;q22.1);RUNX1-RUNX1T1, inv(16)(p13.1q22) or t(16;16 )(p13.1;q22);CBFB-MYH11 \] ;
* (4) The subject is known to have AML central nervous system (CNS) infiltration;
* (5) Have undergone cardiac angioplasty or stent placement within 12 months before signing the informed consent form , or have a history of myocardial infarction, unstable angina, or other clinically significant heart disease;
* (6 ) Active infections (including bacterial, fungal or viral infections) and organ bleeding that cannot be controlled clinically;
* (7) Pregnant or lactating women;
* (8) Participated in any other clinical research within 3 months before signing the informed consent form ;
* (9 ) The researcher believes that it is not suitable to participate in this study;

Conditions3

Interventions3

Related trials

• A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. — Ascentage Pharma Group Inc.
• A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas — The Lymphoma Academic Research Organisation
• A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia — Shanghai Tong Ren Hospital
• A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML — Stichting Hemato-Oncologie voor Volwassenen Nederland
• AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission — The First Affiliated Hospital of Soochow University
• An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. — Servier Affaires Médicales
• Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma — Institute of Hematology & Blood Diseases Hospital, China
• Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma — The First Affiliated Hospital of Soochow University

Browse More Trials